COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER

Abstract

The nominal base case estimate of the cost per quality adjusted life-year for zoledronic acid in the prevention of skeletal complications of prostate cancer is consistent with that of bisphosphonates in breast cancer. However, the cost-effectiveness ratios for bisphosphonates are higher than commonly cited thresholds for conferring cost-effectiveness.